BioMarin posts first $1 billion quarter but cuts full‑year outlook over order timing
BioMarin Pharmaceutical reported third‑quarter 2026 revenue of about $1.025 billion, a 32% year‑over‑year increase, and non‑GAAP diluted EPS of $0.23, up 92% YoY. The company lowered its 2026 full‑year revenue guidance to $3.8‑$3.9 billion and non‑GAAP EPS guidance to $2.80‑$3.10, citing a $70 million deferral of orders from a single international customer. Shares fell roughly 5.12% in after‑hours trading following the release.
Why it matters
The reduced full‑year guidance signals lower revenue and earnings expectations for investors, potentially pressuring the stock price. The $70 million order deferral highlights a timing risk that could affect cash flow in the near term.
Key facts
- 1Q3 2026 revenue was $1.025 billion, up 32% YoY. investing.com
- 2Non‑GAAP diluted EPS for the quarter was $0.23, up 92% YoY. investing.com
- 3Full‑year 2026 revenue guidance was cut to $3.8‑$3.9 billion. investing.com
- 4Full‑year 2026 non‑GAAP EPS guidance was cut to $2.80‑$3.10. investing.com
- 5The company flagged a $70 million order deferral from an international customer. investing.com
- 6After‑hours stock price fell 5.12% to $54.50. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.